# CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

> **NCT04282174** · PHASE2 · WITHDRAWN · sponsor: **Baptist Health South Florida**

## Conditions studied

- Hematologic Diseases
- Hematologic Malignancy
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia
- Chronic Lymphocytic Leukemia

## Interventions

- **DEVICE:** CliniMACS
- **PROCEDURE:** Bone Marrow Transplant
- **DRUG:** Hyperfractionated Total Body Irradiation
- **DRUG:** Thiotepa
- **DRUG:** Cyclophosphamide
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT04282174
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09
- **Primary completion:** 2030-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was split into two new studies before the first participant was enrolled.
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04282174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04282174, "CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04282174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*